Effects of Simvastatin on Biochemical Parameters and Outcome of IVF-ICSI in Pcos Patients : A Prospective Randomized Double Blind Placebo Controlled Trial
20 Years
40 Years
Female
Polycystic Ovary Syndrome
Trial Information
Effects of Simvastatin on Biochemical Parameters and Outcome of IVF-ICSI in Pcos Patients : A Prospective Randomized Double Blind Placebo Controlled Trial
simvastatin reduces cardiovascular risks by improving hypercholesterolemia, reducing
vascular smooth muscle proliferation, ameliorating inflammation, limiting theca-interstitial
proliferation & decreasing steroidogenesis (production of progesterone &
testosterone).Polycystic ovary syndrome (pcos) is associated with increased cardiovascular
risks and is characterized by ovarian theca-interstitial hyperplasia& hyperandrogenism .This
study will test the hypothesis that simvastatin improves biochemical parameters& IVF-ICSI
outcome in Pcos patients.
Inclusion Criteria:
- Pcos patients
- Age <40 years
- FSH<10 IU/L
Exclusion Criteria:
- Endometriosis grade 3 &4
- History of tubal surgery
- Hydrosalpinx
- History of mellitis diabetes
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care
Outcome Measure:
ivf-et outcomes
Outcome Time Frame:
14-20 days
Safety Issue:
No
Principal Investigator
batool hossein rashidi, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Tehran University of Medical Sciences
Authority:
Iran: Ministry of Health
Study ID:
850-39-4796
NCT ID:
NCT00575601
Start Date:
August 2007
Completion Date:
April 2009
Related Keywords:
- Polycystic Ovary Syndrome
- pco
- simvastatin
- ivf
- embryo transfer
- Polycystic Ovary Syndrome
Name | Location |
|---|
